Missense mutations in LRRK2 were first identified as a cause of Parkinson’s disease (PD) in 2004. Subsequent studies showed that these mutations account for up to 10 percent of familial cases, with ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Today, Biogen and Eisai announced they would terminate the Phase 3 ENGAGE and EMERGE trials of aducanumab for early Alzheimer’s disease. A futility analysis run by an independent data-monitoring ...

28 Sep 2022. Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab.The drug slowed decline on the primary endpoint, ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

Alzheimer’s researchers have long wished for better mouse models. That is now coming true. Scientists at the Jackson Laboratory in Bar Harbor, Maine, are cranking out numerous lines that express ...

There was a new feeling in the air at the 12th Clinical Trials on Alzheimer’s Disease conference. It felt good: After decades of failure, the field might finally be turning a corner. The renewed ...

20 Jan 2022. After months of uncertainty, the hammer fell for Biogen: In a draft decision released January 11, the Centers for Medicare and Medicaid Services proposed to cover the anti-amyloid ...

04 May 2023. Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an ...

22 Mar 2024. Old drugs die hard. Despite a string of negative Phase 3 trials, HMTM, a derivative of the malaria drug methylene blue, resurfaced again at AD/PD 2024, held March 5-9 in Lisbon, ...

Dennis Selkoe Co-Director, Brigham and Women's Hospital's Ann Romney Center for Neurologic Diseases; Posted: 11 Nov 2020 The negative vote on Biogen’s aducanumab filing by the FDA Advisory Committee ...

The virus–Alzheimer’s tug of war continues. New data across several studies weaken the proposed, and much-debated, association; its proponents are holding fast. Short-term anti-herpes drug use ...